|
| 37531083 | A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors. | Oncologist | 2024 |
| 36454580 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37865776 | Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT). | J Exp Clin Cancer Res | 2023 |
| 37653066 | Addressing racial and ethnic disparities in AACR project GENIE. | NPJ Precis Oncol | 2023 |
| 37645622 | Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. | Cancer Res Commun | 2023 |
| 37644355 | The association of cancer-related fatigue on the social, vocational and healthcare-related dimensions of cancer survivorship. | J Cancer Surviv | 2023 |
| 37572657 | A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. | Med | 2023 |
| 37768658 | Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. | JAMA Oncol | 2023 |
| 37566240 | Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial. | Clin Cancer Res | 2023 |
| 37419999 | A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events. | Br J Cancer | 2023 |
| 37341839 | Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study. | Support Care Cancer | 2023 |
| 37223888 | The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 |
| 37027812 | Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials. | JCO Precis Oncol | 2023 |
| 36827626 | Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. | J Clin Oncol | 2023 |
| 36670100 | Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. | Cell Death Dis | 2023 |
| 34623509 | Novel classes of immunotherapy for breast cancer. | Breast Cancer Res Treat | 2022 |
| 35705312 | Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. | J Immunother Cancer | 2022 |
| 35638085 | Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. | Eur Urol Open Sci | 2022 |
| 35465733 | A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancer. | Future Oncol | 2022 |
| 35635640 | A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. | Target Oncol | 2022 |
| 35750695 | Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. | Nat Commun | 2022 |
| 36636049 | A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. | J Gastrointest Oncol | 2022 |
| 35939768 | Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. | JCO Precis Oncol | 2022 |
| 35997696 | Role of Lactate Dehydrogenase in Identifying Relapse for Patients With Stage I Testicular Cancer on Surveillance. | J Urol | 2022 |
| 36055464 | Leveraging big data of immune checkpoint blockade response identifies novel potential targets. | Ann Oncol | 2022 |
| 36008705 | Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE. | Br J Cancer | 2022 |
| 35192403 | A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. | JCO Clin Cancer Inform | 2022 |
| 35190802 | Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE. | Clin Cancer Res | 2022 |
| 35130943 | Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. | J Exp Clin Cancer Res | 2022 |
| 34918879 | Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer. | Cancer Med | 2022 |
| 35026412 | Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. | Ann Oncol | 2022 |
| 34931041 | No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. | Br J Cancer | 2022 |
| 35337750 | Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets. | Clin Genitourin Cancer | 2022 |
| 35264434 | Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. | J Immunother Cancer | 2022 |
| 35262412 | Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers. | Thyroid | 2022 |
| 35079688 | Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria. | Eur Heart J Case Rep | 2022 |
| 34734967 | Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. | JAMA Oncol | 2022 |
| 34582333 | Use of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines? | Can Urol Assoc J | 2022 |
| 32907779 | Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. | Eur Urol Oncol | 2021 |
| 33883177 | Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. | Clin Cancer Res | 2021 |
| 33625877 | OncoTree: A Cancer Classification System for Precision Oncology. | JCO Clin Cancer Inform | 2021 |
| 33507821 | Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. | J Clin Oncol | 2021 |
| 33616650 | Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. | J Natl Cancer Inst | 2021 |
| 33811119 | The Future of Clinical Trial Design in Oncology. | Cancer Discov | 2021 |
| 33527137 | The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. | J Natl Cancer Inst | 2021 |
| 34492632 | Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer. | J Natl Compr Canc Netw | 2021 |
| 34389618 | First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. | J Immunother Cancer | 2021 |
| 34417144 | Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. | Clin Colorectal Cancer | 2021 |
| 34446728 | Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. | Nat Commun | 2021 |
| 34711609 | Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response. | Cancer Res | 2021 |